$EGRX
EAGLE PHARMACEUTICALS, INC.

2017 Q2 Form 10-Q Financial Statement

#000082787117000007 Filed on August 09, 2017

View on sec.gov

Income Statement

Concept 2017 Q2 2016 Q2
Revenue $50.11M $40.92M
YoY Change 22.46% 581.74%
Cost Of Revenue $8.910M $11.47M
YoY Change -22.34% 242.68%
Gross Profit $41.20M $29.45M
YoY Change 39.92% 1009.46%
Gross Profit Margin 82.22% 71.96%
Selling, General & Admin $23.28M $11.99M
YoY Change 94.16% 134.59%
% of Gross Profit 56.51% 40.72%
Research & Development $6.684M $3.799M
YoY Change 75.94% -35.37%
% of Gross Profit 16.22% 12.9%
Depreciation & Amortization $940.0K $320.0K
YoY Change 193.75% 3100.0%
% of Gross Profit 2.28% 1.09%
Operating Expenses $44.21M $27.26M
YoY Change 62.15% 90.15%
Operating Profit $5.902M $13.66M
YoY Change -56.78% -263.84%
Interest Expense $40.00K $3.000K
YoY Change 1233.33% 0.0%
% of Operating Profit 0.68% 0.02%
Other Income/Expense, Net -$26.00K $27.00K
YoY Change -196.3% 440.0%
Pretax Income $5.876M $13.68M
YoY Change -57.06% -264.26%
Income Tax $1.373M $584.0K
% Of Pretax Income 23.37% 4.27%
Net Earnings $4.503M $13.10M
YoY Change -65.62% -260.19%
Net Earnings / Revenue 8.99% 32.01%
Basic Earnings Per Share $0.30 $0.84
Diluted Earnings Per Share $0.28 $0.80
COMMON SHARES
Basic Shares Outstanding 15.22M shares 15.64M shares
Diluted Shares Outstanding 16.10M shares

Balance Sheet

Concept 2017 Q2 2016 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $55.40M $75.60M
YoY Change -26.72% -27.1%
Cash & Equivalents $55.39M $75.56M
Short-Term Investments
Other Short-Term Assets $688.0K $328.0K
YoY Change 109.76% 65.66%
Inventory $3.587M $6.363M
Prepaid Expenses
Receivables $53.23M $52.03M
Other Receivables $0.00 $0.00
Total Short-Term Assets $123.9M $135.5M
YoY Change -8.59% 12.4%
LONG-TERM ASSETS
Property, Plant & Equipment $3.768M $2.813M
YoY Change 33.95% 652.14%
Goodwill $39.74M
YoY Change
Intangibles $31.95M $10.96M
YoY Change 191.51%
Long-Term Investments
YoY Change
Other Assets $578.0K $94.00K
YoY Change 514.89% -9.62%
Total Long-Term Assets $96.31M $13.87M
YoY Change 594.55% 2801.05%
TOTAL ASSETS
Total Short-Term Assets $123.9M $135.5M
Total Long-Term Assets $96.31M $13.87M
Total Assets $220.2M $149.4M
YoY Change 47.41% 23.41%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $12.15M $11.43M
YoY Change 6.27% 138.99%
Accrued Expenses $18.68M $23.34M
YoY Change -19.95% 72.37%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $31.95M $35.78M
YoY Change -10.69% 45.56%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $22.90M $5.800M
YoY Change 294.83%
Total Long-Term Liabilities $22.90M $5.800M
YoY Change 294.83%
TOTAL LIABILITIES
Total Short-Term Liabilities $31.95M $35.78M
Total Long-Term Liabilities $22.90M $5.800M
Total Liabilities $54.80M $41.50M
YoY Change 32.05% 68.7%
SHAREHOLDERS EQUITY
Retained Earnings $1.768M -$94.91M
YoY Change -101.86% -3.31%
Common Stock $16.00K $15.00K
YoY Change 6.67% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost) $62.31M
YoY Change
Treasury Stock Shares 896.7K shares
Shareholders Equity $165.4M $107.8M
YoY Change
Total Liabilities & Shareholders Equity $220.2M $149.4M
YoY Change 47.41% 23.41%

Cashflow Statement

Concept 2017 Q2 2016 Q2
OPERATING ACTIVITIES
Net Income $4.503M $13.10M
YoY Change -65.62% -260.19%
Depreciation, Depletion And Amortization $940.0K $320.0K
YoY Change 193.75% 3100.0%
Cash From Operating Activities $37.55M -$2.630M
YoY Change -1527.76% -78.3%
INVESTING ACTIVITIES
Capital Expenditures -$200.0K -$100.0K
YoY Change 100.0% -65.52%
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00
YoY Change -100.0%
Cash From Investing Activities -$200.0K -$100.0K
YoY Change 100.0% -99.87%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -9.660M 0.000
YoY Change -100.0%
NET CHANGE
Cash From Operating Activities 37.55M -2.630M
Cash From Investing Activities -200.0K -100.0K
Cash From Financing Activities -9.660M 0.000
Net Change In Cash 27.69M -2.730M
YoY Change -1114.29% -96.83%
FREE CASH FLOW
Cash From Operating Activities $37.55M -$2.630M
Capital Expenditures -$200.0K -$100.0K
Free Cash Flow $37.75M -$2.530M
YoY Change -1592.09% -78.61%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2017
dei Document Type
DocumentType
10-Q
dei Amendment Flag
AmendmentFlag
false
dei Document Period End Date
DocumentPeriodEndDate
2017-06-30
dei Entity Central Index Key
EntityCentralIndexKey
0000827871
CY2017Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
15169241 shares
dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
dei Entity Registrant Name
EntityRegistrantName
EAGLE PHARMACEUTICALS, INC.
CY2016Q4 egrx Accrued Product Costs Current
AccruedProductCostsCurrent
2856000 USD
CY2017Q2 egrx Accrued Product Costs Current
AccruedProductCostsCurrent
3735000 USD
CY2016Q4 egrx Accrued Researchand Development Current
AccruedResearchandDevelopmentCurrent
3528000 USD
CY2017Q2 egrx Accrued Researchand Development Current
AccruedResearchandDevelopmentCurrent
1470000 USD
CY2016Q4 egrx Advancestocommercialmanufactures
Advancestocommercialmanufactures
7600000 USD
CY2017Q2 egrx Advancestocommercialmanufactures
Advancestocommercialmanufactures
4863000 USD
egrx Increase Decreasein Prepaid Expenseand Other Current Assets Total
IncreaseDecreaseinPrepaidExpenseandOtherCurrentAssetsTotal
-319000 USD
egrx Increase Decreasein Prepaid Expenseand Other Current Assets Total
IncreaseDecreaseinPrepaidExpenseandOtherCurrentAssetsTotal
307000 USD
CY2017Q2 egrx Number Of Products
NumberOfProducts
5 product
CY2016Q4 egrx Prepaid Fda User Fee
PrepaidFDAUserFee
1592000 USD
CY2017Q2 egrx Prepaid Fda User Fee
PrepaidFDAUserFee
531000 USD
CY2016Q4 egrx Prepaid Research And Development
PrepaidResearchAndDevelopment
21000 USD
CY2017Q2 egrx Prepaid Research And Development
PrepaidResearchAndDevelopment
937000 USD
CY2016Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
14716000 USD
CY2017Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
12148000 USD
CY2016Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
42194000 USD
CY2017Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
53230000 USD
CY2016Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
25237000 USD
CY2017Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
18680000 USD
CY2016Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
2094000 USD
CY2017Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
3443000 USD
CY2016Q4 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
9068000 USD
CY2017Q2 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
5128000 USD
CY2016Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
6003000 USD
CY2017Q2 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
3798000 USD
CY2016Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
213872000 USD
CY2017Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
225892000 USD
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7890000 USD
CY2016Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2420000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5289000 USD
CY2017Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3697000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7890000 USD
CY2016Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
156000 USD
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
260000 USD
CY2017Q2 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
711000 USD
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1423000 USD
CY2016Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1448172 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1359519 shares
CY2017Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1581586 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1552064 shares
CY2016Q4 us-gaap Assets
Assets
214320000 USD
CY2017Q2 us-gaap Assets
Assets
220179000 USD
CY2016Q4 us-gaap Assets Current
AssetsCurrent
109110000 USD
CY2017Q2 us-gaap Assets Current
AssetsCurrent
123866000 USD
us-gaap Business Combination Consideration Transferred Liabilities Incurred
BusinessCombinationConsiderationTransferredLiabilitiesIncurred
6370000 USD
us-gaap Business Combination Consideration Transferred Liabilities Incurred
BusinessCombinationConsiderationTransferredLiabilitiesIncurred
0 USD
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
395000 USD
us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
848000 USD
CY2016Q4 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
1012000 USD
CY2017Q2 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
1125000 USD
CY2016Q4 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
22129000 USD
CY2017Q2 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
22864000 USD
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
79083000 USD
CY2016Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
75563000 USD
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
52820000 USD
CY2017Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
55385000 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-3520000 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
2565000 USD
CY2017Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2016Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2017Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2016Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000 shares
CY2017Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000 shares
CY2016Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
15890862 shares
CY2017Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
16065987 shares
CY2016Q4 us-gaap Common Stock Value
CommonStockValue
16000 USD
CY2017Q2 us-gaap Common Stock Value
CommonStockValue
16000 USD
CY2016Q2 us-gaap Cost Of Goods Sold
CostOfGoodsSold
7181000 USD
us-gaap Cost Of Goods Sold
CostOfGoodsSold
19948000 USD
CY2017Q2 us-gaap Cost Of Goods Sold
CostOfGoodsSold
8910000 USD
us-gaap Cost Of Goods Sold
CostOfGoodsSold
19675000 USD
CY2016Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
28643000 USD
CY2017Q2 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
20275000 USD
us-gaap Deferred Income Taxes And Tax Credits
DeferredIncomeTaxesAndTaxCredits
0 USD
us-gaap Deferred Income Taxes And Tax Credits
DeferredIncomeTaxesAndTaxCredits
8368000 USD
us-gaap Depreciation
Depreciation
296000 USD
us-gaap Depreciation
Depreciation
432000 USD
CY2016Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.84
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.78
CY2017Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.30
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.80
CY2016Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.80
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.74
CY2017Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.28
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.70
CY2016Q2 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.04
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.05
CY2017Q2 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.23
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.29
CY2016Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
948000 USD
CY2017Q2 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
2371000 USD
CY2017Q2 us-gaap Finite Lived Intangible Assets Amortization Expense After Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
17827000 USD
CY2017Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
1423000 USD
CY2017Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
3246000 USD
CY2017Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
3289000 USD
CY2017Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
3143000 USD
CY2017Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
3021000 USD
CY2016Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
34320000 USD
CY2017Q2 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
34320000 USD
CY2016Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
33372000 USD
CY2017Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
31949000 USD
CY2016Q2 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
0 USD
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
1750000 USD
CY2017Q2 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
0 USD
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
0 USD
CY2016Q4 us-gaap Goodwill
Goodwill
39743000 USD
CY2017Q2 us-gaap Goodwill
Goodwill
39743000 USD
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0 USD
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0 USD
us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
0 USD
us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
0 USD
CY2016Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
13683000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
12805000 USD
CY2017Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
5876000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
38548000 USD
CY2016Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
584000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
603000 USD
CY2017Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1373000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
11121000 USD
us-gaap Income Taxes Paid
IncomeTaxesPaid
0 USD
us-gaap Income Taxes Paid
IncomeTaxesPaid
5585000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
7574000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-2568000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
25760000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
11036000 USD
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-1069000 USD
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-6557000 USD
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-6000000 USD
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
0 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-8679000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
848000 USD
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-49000 USD
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
26000 USD
CY2016Q2 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
829633 shares
us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
890209 shares
CY2017Q2 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
880838 shares
us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
896547 shares
CY2016Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
33372000 USD
CY2017Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
31949000 USD
us-gaap Interest Expense
InterestExpense
0 USD
us-gaap Interest Expense
InterestExpense
66000 USD
CY2016Q2 us-gaap Interest Expense Other
InterestExpenseOther
3000 USD
us-gaap Interest Expense Other
InterestExpenseOther
4000 USD
CY2017Q2 us-gaap Interest Expense Other
InterestExpenseOther
40000 USD
us-gaap Interest Expense Other
InterestExpenseOther
67000 USD
CY2016Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
708000 USD
CY2017Q2 us-gaap Inventory Finished Goods
InventoryFinishedGoods
1194000 USD
CY2016Q4 us-gaap Inventory Net
InventoryNet
2739000 USD
CY2017Q2 us-gaap Inventory Net
InventoryNet
3587000 USD
CY2016Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
1131000 USD
CY2017Q2 us-gaap Inventory Raw Materials
InventoryRawMaterials
1393000 USD
CY2016Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
900000 USD
CY2017Q2 us-gaap Inventory Work In Process
InventoryWorkInProcess
1000000 USD
CY2016Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
30000 USD
us-gaap Investment Income Interest
InvestmentIncomeInterest
51000 USD
CY2017Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
14000 USD
us-gaap Investment Income Interest
InvestmentIncomeInterest
17000 USD
CY2016Q2 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
156000 USD
us-gaap Lease And Rental Expense
LeaseAndRentalExpense
318000 USD
CY2017Q2 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
157000 USD
us-gaap Lease And Rental Expense
LeaseAndRentalExpense
319000 USD
CY2016Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
214320000 USD
CY2017Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
220179000 USD
CY2016Q4 us-gaap Liabilities Current
LiabilitiesCurrent
40965000 USD
CY2017Q2 us-gaap Liabilities Current
LiabilitiesCurrent
31953000 USD
CY2016Q1 us-gaap Loss Contingency Patents Allegedly Infringed Number
LossContingencyPatentsAllegedlyInfringedNumber
2 patent
CY2016Q2 us-gaap Marketing And Advertising Expense
MarketingAndAdvertisingExpense
3318000 USD
us-gaap Marketing And Advertising Expense
MarketingAndAdvertisingExpense
5721000 USD
CY2017Q2 us-gaap Marketing And Advertising Expense
MarketingAndAdvertisingExpense
8792000 USD
us-gaap Marketing And Advertising Expense
MarketingAndAdvertisingExpense
14728000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
0 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-21663000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-4004000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-884000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
484000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
25112000 USD
CY2016Q2 us-gaap Net Income Loss
NetIncomeLoss
13099000 USD
us-gaap Net Income Loss
NetIncomeLoss
12202000 USD
CY2017Q2 us-gaap Net Income Loss
NetIncomeLoss
4503000 USD
us-gaap Net Income Loss
NetIncomeLoss
27427000 USD
CY2016Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
13099000 USD
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
12202000 USD
CY2017Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
4503000 USD
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
27427000 USD
CY2016Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
27000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
47000 USD
CY2017Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-26000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-50000 USD
CY2016Q2 us-gaap Operating Expenses
OperatingExpenses
27262000 USD
us-gaap Operating Expenses
OperatingExpenses
57750000 USD
CY2017Q2 us-gaap Operating Expenses
OperatingExpenses
44206000 USD
us-gaap Operating Expenses
OperatingExpenses
88303000 USD
CY2016Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
13656000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
12758000 USD
CY2017Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
5902000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
38598000 USD
CY2017Q2 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
2828000 USD
CY2017Q2 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
117000 USD
CY2017Q2 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
395000 USD
CY2017Q2 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
674000 USD
CY2017Q2 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
670000 USD
CY2017Q2 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
638000 USD
CY2017Q2 us-gaap Operating Leases Future Minimum Payments Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear
334000 USD
CY2016Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1688000 USD
CY2017Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1106000 USD
CY2016Q4 us-gaap Other Assets Current
OtherAssetsCurrent
355000 USD
CY2017Q2 us-gaap Other Assets Current
OtherAssetsCurrent
688000 USD
CY2016Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
136000 USD
CY2017Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
578000 USD
CY2016Q2 us-gaap Other Sales Revenue Net
OtherSalesRevenueNet
0 USD
us-gaap Other Sales Revenue Net
OtherSalesRevenueNet
6000000 USD
CY2017Q2 us-gaap Other Sales Revenue Net
OtherSalesRevenueNet
0 USD
us-gaap Other Sales Revenue Net
OtherSalesRevenueNet
25000000 USD
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
0 USD
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
25311000 USD
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
0 USD
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
482000 USD
us-gaap Payments To Acquire Businesses Gross
PaymentsToAcquireBusinessesGross
4850000 USD
us-gaap Payments To Acquire Businesses Gross
PaymentsToAcquireBusinessesGross
0 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
904000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
884000 USD
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
62000000 USD
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
0 USD
CY2016Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1500000 shares
CY2017Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1500000 shares
us-gaap Share Based Compensation
ShareBasedCompensation
5289000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
7890000 USD
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
4130000 USD
CY2016Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2017Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2016Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2017Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2016Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2017Q2 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2016Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
11357000 USD
CY2017Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
11664000 USD
CY2016Q4 us-gaap Prepaid Insurance
PrepaidInsurance
135000 USD
CY2017Q2 us-gaap Prepaid Insurance
PrepaidInsurance
535000 USD
CY2016Q4 us-gaap Prepaid Taxes
PrepaidTaxes
1654000 USD
CY2017Q2 us-gaap Prepaid Taxes
PrepaidTaxes
4110000 USD
us-gaap Proceeds From Divestiture Of Businesses
ProceedsFromDivestitureOfBusinesses
6500000 USD
us-gaap Proceeds From Sale Maturity And Collection Of Shortterm Investments
ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
62000000 USD
us-gaap Proceeds From Sale Maturity And Collection Of Shortterm Investments
ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
0 USD
us-gaap Proceeds From Sale Of Productive Assets
ProceedsFromSaleOfProductiveAssets
1750000 USD
us-gaap Proceeds From Sale Of Productive Assets
ProceedsFromSaleOfProductiveAssets
0 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
4130000 USD
CY2016Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3316000 USD
CY2017Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3768000 USD
CY2017Q2 us-gaap Purchase Obligation
PurchaseObligation
14994000 USD
CY2017Q2 us-gaap Purchase Obligation Due After Fifth Year
PurchaseObligationDueAfterFifthYear
0 USD
CY2017Q2 us-gaap Purchase Obligation Due In Fifth Year
PurchaseObligationDueInFifthYear
0 USD
CY2017Q2 us-gaap Purchase Obligation Due In Fourth Year
PurchaseObligationDueInFourthYear
0 USD
CY2017Q2 us-gaap Purchase Obligation Due In Second Year
PurchaseObligationDueInSecondYear
0 USD
CY2017Q2 us-gaap Purchase Obligation Due In Third Year
PurchaseObligationDueInThirdYear
0 USD
CY2017Q2 us-gaap Purchase Obligation Future Minimum Payments Remainder Of Fiscal Year
PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear
14994000 USD
CY2016Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3799000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9320000 USD
CY2017Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6684000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
14209000 USD
CY2016Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-25659000 USD
CY2017Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
1768000 USD
CY2016Q2 us-gaap Royalty Expense
RoyaltyExpense
4292000 USD
us-gaap Royalty Expense
RoyaltyExpense
6114000 USD
CY2017Q2 us-gaap Royalty Expense
RoyaltyExpense
4910000 USD
us-gaap Royalty Expense
RoyaltyExpense
12140000 USD
CY2016Q2 us-gaap Royalty Revenue
RoyaltyRevenue
31311000 USD
us-gaap Royalty Revenue
RoyaltyRevenue
40779000 USD
CY2017Q2 us-gaap Royalty Revenue
RoyaltyRevenue
37404000 USD
us-gaap Royalty Revenue
RoyaltyRevenue
73911000 USD
CY2016Q2 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
9607000 USD
us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
23729000 USD
CY2017Q2 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
12704000 USD
us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
27990000 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P4Y
CY2016Q2 us-gaap Sales Revenue Net
SalesRevenueNet
40918000 USD
us-gaap Sales Revenue Net
SalesRevenueNet
70508000 USD
CY2017Q2 us-gaap Sales Revenue Net
SalesRevenueNet
50108000 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.3131
us-gaap Sales Revenue Net
SalesRevenueNet
126901000 USD
CY2016Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
11990000 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
24118000 USD
CY2017Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
23702000 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
42279000 USD
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2017Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2017Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.3435
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.3156
CY2017Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0179
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0179
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.3697
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0153
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0190
CY2017Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0218
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0242
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0129
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0129
CY2016Q3 us-gaap Stock Repurchase Program Authorized Amount1
StockRepurchaseProgramAuthorizedAmount1
75000000.0 USD
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
151226000 USD
CY2017Q2 us-gaap Stockholders Equity
StockholdersEquity
165362000 USD
CY2016Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
566838 shares
CY2017Q2 us-gaap Treasury Stock Shares
TreasuryStockShares
896746 shares
CY2016 us-gaap Treasury Stock Shares Acquired
TreasuryStockSharesAcquired
566838 shares
CY2017Q2 us-gaap Treasury Stock Shares Acquired
TreasuryStockSharesAcquired
329908 shares
us-gaap Treasury Stock Shares Acquired
TreasuryStockSharesAcquired
329908 shares
CY2016Q4 us-gaap Treasury Stock Value
TreasuryStockValue
37003000 USD
CY2017Q2 us-gaap Treasury Stock Value
TreasuryStockValue
62314000 USD
CY2016 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
37000000 USD
CY2017Q2 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
25311000 USD
us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
25311000 USD
us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
25300000 USD
CY2017Q2 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0 USD
CY2016Q2 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
16466020 shares
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
16526596 shares
CY2017Q2 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
16100615 shares
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
16135276 shares
CY2016Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
15636387 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
15636387 shares
CY2017Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
15219777 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
15238729 shares
us-gaap Basis Of Accounting
BasisOfAccounting
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Interim Condensed Consolidated Financial Statements</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (&#8220;U.S. GAAP&#8221;) for interim information and pursuant to the rules and regulations of the Securities and Exchange Commission (the &#8220;SEC&#8221;) for reporting on Form 10-Q. Accordingly, certain information and footnote disclosures required for complete financial statements are not included herein. The condensed consolidated balance sheet at December 31, 2016 was derived from audited financial statements, but certain information and footnote disclosures normally included in the Company's annual consolidated financial statements have been condensed or omitted. In the opinion of management, all adjustments (consisting only of normal recurring adjustments) necessary for the fair presentation of the financial information for the interim periods reported have been made.&#160;Results of operations for the </font><font style="font-family:inherit;font-size:10pt;">three and six months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;"> are not necessarily indicative of the results for the year ending December 31, </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;"> or any period thereafter. These unaudited interim condensed consolidated financial statements should be read in conjunction with the audited financial statements and related notes included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2016, filed with the SEC on March 15, 2017. Unless otherwise indicated or required by context, reference throughout to the "Company," "Eagle Pharmaceuticals," "Eagle," "we," "us" or "our" mean Eagle Pharmaceuticals, Inc., a Delaware corporation and its subsidiary, Eagle Biologics, Inc., and references to "Eagle Biologics" mean Eagle Biologics, Inc.</font></div></div>
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Reclassifications</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certain reclassifications have been made to prior year amounts to conform with the current year presentation.</font></div></div>
us-gaap Use Of Estimates
UseOfEstimates
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These financial statements are presented in U.S. dollars and are prepared in accordance with U.S. GAAP. The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed financial statements including disclosure of contingent assets and contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period and accompanying notes. The Company's critical accounting policies are those that are both most important to the Company's financial condition and results of operations and require the most difficult, subjective or complex judgments on the part of management in their application, often as a result of the need to make estimates about the effect of matters that are inherently uncertain. Because of the uncertainty of factors surrounding the estimates or judgments used in the preparation of the financial statements, actual results may materially vary from these estimates.</font></div></div>

Files In Submission

Name View Source Status
0000827871-17-000007-index-headers.html Edgar Link pending
0000827871-17-000007-index.html Edgar Link pending
0000827871-17-000007.txt Edgar Link pending
0000827871-17-000007-xbrl.zip Edgar Link pending
egrx-20170630.xml Edgar Link completed
egrx-20170630.xsd Edgar Link pending
egrx-20170630_cal.xml Edgar Link unprocessable
egrx-20170630_def.xml Edgar Link unprocessable
egrx-20170630_lab.xml Edgar Link unprocessable
egrx-20170630_pre.xml Edgar Link unprocessable
egrx_q2x2017.htm Edgar Link pending
exhibit311q22017.htm Edgar Link pending
exhibit312q22017.htm Edgar Link pending
exhibit321q22017.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending